肝癌miR-142-5p的表达及其靶基因预测

被引:0
|
作者
刘辉 [1 ]
任长蓉 [1 ]
张凯虔 [1 ]
孙启玉 [1 ]
高英梅 [2 ]
李剑 [1 ]
机构
[1] 承德医学院附属医院/河北省泛血管重点实验室
[2] 河北省迁安市人民医院
关键词
原发性肝细胞癌; miR-142-5p; 靶基因;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
摘要
目的:探讨原发性肝细胞癌(HCC)癌组织及血浆miR-142-5p的表达与病理特征的关系,并对miR-142-5p靶基因进行预测。方法:以我院就诊40例乙型肝炎病毒相关HCC患者,35例乙型肝炎病毒相关慢性肝病(CHB)患者为研究对象。对HCC患者癌组织、癌旁组织及血浆miR-142-5p含量进行检测,分析miR-142-5p与肝癌病理特征关系。同时建立受试者工作曲线(ROC)分析miR-142-5p诊断价值。应用生物信息学对miR-142-5p的靶基因进一步预测分析。结果:HCC患者癌组织miR-142-5p含量明显低于癌旁组织。HCC患者血浆miR-142-5p含量和癌组织miR-142-5p含量呈正相关,且明显低于CHB患者。HCC患者癌组织miR-142-5p及血浆miR-142-5p含量均与肝癌分化程度及BCLC分期相关。ROC分析显示miR-142-5p具有HCC诊断价值,在HCC患者癌组织及血浆中诊断HCC的ROC下面积分别为0.692和0.755。生物信息预测显示6个数据库交叉存在16个miR-142-5p靶基因,进一步GO和KEGG分析显示miR-142-5p通过多种途径参与肝癌的发生发展。结论:miR-142-5p在HCC患者癌组织及血浆中低表达具有诊断价值,和肝癌的发生发展密切相关。
引用
收藏
页码:230 / 234
页数:5
相关论文
共 13 条
  • [1] 原发性肝癌诊疗指南(2024年版)
    中华人民共和国国家卫生健康委员会医政司
    [J]. 协和医学杂志, 2024, 15 (03) : 532 - 559
  • [2] 慢性乙型肝炎防治指南(2022年版)
    中华医学会肝病学分会
    中华医学会感染病学分会
    [J]. 中华传染病杂志, 2023, 41 (01)
  • [3] Diagnostic and prognostic value of miR-486-5p; miR-451a; miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction..[J].Xu Liwenjing;Tian Lu;Yan Zhenrong;Wang Jia;Xue Tingyun;Sun Qiyu.Heart and vessels.2022, 3
  • [4] MicroRNA-29a and MicroRNA-124 as novel biomarkers for hepatocellular Carcinoma..[J].ShehabEldeen Somaia;Metwaly Mohamed F;Saber Safa M;ElKousy Salah M;Badr Eman Ae;Essa Abdallah.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.2022, 2
  • [5] MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1
    Sun, Yongjie
    Shi, Peng
    Wu, Qi
    Liu, Bingqiang
    Yu, Zetao
    Jia, Hongtao
    Chang, Hong
    [J]. HUMAN CELL, 2021, 34 (06) : 1788 - 1799
  • [6] miR-224 Regulates the Aggressiveness of Hepatoma Cells Through the IL-6/STAT3/SMAD4 Pathway
    An, Fangmei
    Wu, Xiongbo
    Zhang, Yunan
    Chen, Dayang
    Zhang, Guoqiang
    Lin, Yexin
    Wu, Fang
    Ding, Junli
    Xia, Min
    Zhan, Qiang
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2021, 32 (06): : 532 - 542
  • [7] MicroRNA-26a systemic administration attenuates tumor formation in hepatocellular carcinoma mouse model
    Badr, Abeer M.
    El-Ahwany, Eman
    Goda, Lamiaa
    Nagy, Faten
    Helal, Noha
    El Deeb, Somaya
    [J]. PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 34 (03) : 925 - 932
  • [8] MiR-142-5p Suppresses Lung Cancer Cell Metastasis by Targeting Yin Yang 1 to Regulate Epithelial-Mesenchymal Transition
    Zhang, Qiao
    Liu, Hongfei
    Zhang, Jian
    Shan, Li
    Yibureyimu, Bumaireyimu
    Nurlan, Alima
    Aerxiding, Patiguli
    Luo, Qin
    [J]. CELLULAR REPROGRAMMING, 2020, 22 (06) : 328 - 336
  • [9] ERK/MAPK signalling pathway and tumorigenesis
    Guo, Yan-Jun
    Pan, Wei-Wei
    Liu, Sheng-Bing
    Shen, Zhong-Fei
    Xu, Ying
    Hu, Ling-Ling
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 19 (03) : 1997 - 2007
  • [10] miR-142-5p regulates pancreatic cancer cell proliferation and apoptosis by regulation of RAP1A
    Yao, Rong
    Xu, Lijuan
    Wei, Bin
    Qian, Zhaoye
    Wang, Jiru
    Hui, Hongxia
    Sun, Yuan
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)